Roche’s Carmot Therapeutics acquisition brings three clinical-stage assets that the companies say could be best-in-class drugs for metabolic disorders. In addition to standalone use, Roche sees the Carmot molecules as part of potential combinations with its own drug candidates.
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Bayer opens its new cell therapy manufacturing facility as it prepares a Parkinson’s disease cell therapy for Phase 2 testing. The new 100,000 square foot facility also has space for manufacturing other cell therapies in the pharma giant’s pipeline.
Caribou Biosciences’ CRISPR approach to cell therapy sparked strong investor interest, enabling the clinical-stage biotech to upsize its IPO and raise $304 million in the biggest life sciences IPO this week. Absci, Sophia Genetics, and Cytek Biosciences also priced IPOs.
The prize went to Jennifer Doudna of the University of California Berkeley and Emmanuelle Charpentier of the Max Planck Institute. Charpentier published her research on the biology behind the technology in 2011 and collaborated with Doudna. The two discovered it was possible to control the mechanism.
The journal, Rapid Reviews: COVID-19, will use artificial intelligence to scour preprint servers for promising research and allow it to be peer reviewed. Preprint studies have proliferated amid the Covid-19 pandemic, raising concerns about misinformation.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The algorithm is not designed to replace consumer-facing devices. But while most smart watches track electrical signals from the heart, Eko focuses on sound as a means to improve the work of front-line clinicians.
Eko Devices has raised $20 million in a Series B funding round for a combined stethoscope and ECG device powered by machine learning algorithms in the cardiac care field.
The tool harnesses Mayo Clinic's cardiovascular database and expertise in heart disease screening combined with Eko's cardiac monitoring platform.
Kyoto University's Tasuku Honjo and MD Anderson's James Allison will share the prize for work that led to immunotherapy drugs like Keytruda and Yervoy.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The decision in favor of Broad Institute of MIT and Harvard by a panel of judges at the US Court of Appeals for the Federal Circuit leaves UC Berkeley with few options to appeal further.
The startup's tool sits in the exam room, and the doctor talks to the patient throughout the appointment. Afterward, the notes are sitting in the EMR waiting for the physician to review and sign.
FDA slaps clinical hold on Crispr Therapeutics and Vertex Pharmaceuticals' upcoming gene-editing trial.
The device can be used in a doctor's office and could be prescribed to heart disease patients to support remote monitoring and reduce readmissions.
As the company’s smart fabric technology has evolved, so has the understanding of sensors and their potential applications from would-be customers.